Introduction
Chronic lymphocytic leukemia (CLL) is a frequent malignancy composed by CD5+ B lymphocytes, predominates in older people and has a variable clinical course. The median survival of patients with CLL is about 10 years, but the individual prognosis is extremely variable. Whereas in some patients the disease runs an indolent clinical course and their life span is not shortened, in others the disease has an aggressive behavior with a survival of less than 2-3 years. 1, 2 Management of patients with CLL is one of the most challenging situations in hemato-oncology. For decades treatment of this disease revolved around the use of alkylating agents with little or no impact on the natural history of the disease. The introduction in the late eighties of purine analogs signified an important breakthrough in the management of CLL. More recently, chemoimmunotherapy has emerged as the new paradigm for therapy of CLL. [3] [4] [5] Whether new treatments, along with better general medical care, improve survival of patients with CLL is not completely clear. The analysis of historical series suggests a better survival for patients treated with modern therapies, but these analyses are biased by different median follow up times and do not take into consideration the natural increase in the life-expectancy of the general population. [4] [5] [6] [7] In addition, recent randomized studies demonstrate a longer progression-free, but not a longer overall survival, in patients receiving newer treatments. 8, 9 Yet the advantage of a given therapy over another in randomized studies, taking overall survival as endpoint, is difficult to establish because of 
Patients and Methods

Patients
In total, 929 patients diagnosed with CLL between January 1980 and December 2008 and followed at the Hospital Clínic of Barcelona were evaluated. All patients were diagnosed in agreement with the National Cancer Institute-Working Group Criteria. 12 In addition by excluding patients diagnosed before 1980 we assured that diagnosis was confirmed by flow-cytometry in all patients. Demographic characteristics and clinical and laboratory features at presentation, as well as treatment modalities and follow-up data, were obtained from a database that has been prospectively managed from the 1970s onwards.
Study design
Changes in prognosis over the time were investigated by comparing the relative survival and disease-specific incidence mortality between 451 patients diagnosed from 1980 to 1994 and 365 patients diagnosed from 1995 to 2004.
We limited the year of diagnosis of patients in the second cohort to 2004 to guarantee a minimum follow-up period of four years until the study closing date on December 31, 2008.
Statistical methods
Actuarial survival curves were estimated by the method of Kaplan and
Meier and compared by the log-rank test. Relative survival was calculated according to both the cohort method proposed by Dickman et al. 13 
Results
Characteristics of the series at diagnosis
The principal characteristics of the whole series and of the two cohorts of patients according to the year of diagnosis are shown in Table 1 . Median age at presentation was higher in patients diagnosed in 1980-1994 than in those seen from 1995 to 2004 (68 vs. 64 years, p=0.005). The distribution by age groups showed a shift towards younger age at diagnosis in the more recent cohort, with a significant increase in the proportion of patients younger than 70 (55.9% vs. 63%, p=0.039). There was a preponderance of males in both groups (54.3% vs.
58.4%, p=NS).
The proportion of patients in low-risk clinical stage (Binet A) at diagnosis 
Treatment modalities
Not unexpectedly, most of the patients diagnosed in 1980-1994 who required treatment received alkylating agents (96.4%). Since 1995, the proportion of patients who were given purine analogs, alone or in combination with other agents, increased (Table 2) . Moreover, the number of individuals receiving hemopoietic stem-cell transplantation was higher in the period 1995- transplants were more frequently performed in the second cohort, with allogeneic reduced-intensity conditioning transplantation being only performed in that group. When treatment modality was broken-down according to patients' age, differences in treatment were concentrated in patients younger than 70 years (Table S1 ). Almost all patients under the age of 70 with advanced stage (Binet's B/C) at diagnosis were treated (Table S2 ).
Survival
After a median follow-up of 5.9 years (range: 0.1 -25.4 years), 500 (55%) of the 914 assessable patients have died. Of those censored alive, 349
were still alive and 65 (7.1% of the whole series) were lost to follow-up when the study was closed. Median survival for the whole series was 8.8 (95% CI: 8.0 -9.5) years from diagnosis, and 25% of patients were projected to survive 16 years or longer ( Figure 1 ). Kaplan-Meier survival curves according to Binet stage at diagnosis are depicted in Figure 2 , whereas survival of all patients with CLL in comparison to that of the general population is shown in Figure 3 . When demographic effects of age, sex and year of diagnosis were compensated, a marked effect of the disease on patients' life-expectancy was observed. Indeed, survival of the patients at 5, 10 and 15 years from diagnosis was 80%, 56%, and 49%, respectively, of that expected in the general population. Survival of patients in Binet stage A began to diverge from that of the general population after 5 years from diagnosis and remained at 72% of the theoretical survival 10 years after diagnosis. In contrast, patients in Binet stage B/C had a significantly higher mortality starting from the first year of follow-up and their 10-year survival was 29% of that expected in the general population.
Relative survivals of patients diagnosed in 1980-1994 and 1995-2004 Finally, there was a trend for a greater improvement of relative survival in males than in females (p=0.057).
The 5-year and 10-year mortality attributable to CLL significantly decreased from the first to the second period, this reduction being more striking at 5 years after diagnosis (Table 3 ). The increased relative survival in the more recent period was driven by patients who where younger than 70 years with Binet stages B/C at diagnosis, this being the only subgroup of patients whose outcome improved over the time (Figure 6 ). 
Discussion
Modern therapy has dramatically improved response rate and progression-free survival in patients with CLL. However, CLL continues being incurable and the impact of newer therapies on overall survival is far from being clear. Although studies based on historical controls show that survival seems to be improving 4,5,7 these analyses cannot segregate the benefit provided by newer therapies (and better general medical care) from the natural increase in the life-expectancy of the general population.
4,5
The study of large series from single institutions may offer important information regarding prognosis and survival of patients with CLL over the time.
The Hospital Clínic of Barcelona is a general hospital, serving an area of 500,000 inhabitants, which provides both primary and specialized care and is also a referral center for CLL. Against this background, we analyzed a large series of patients prospectively registered in our database at diagnosis and In spite of the overall poor prognosis, we also found the relative survival of patients with CLL is improving, particularly in younger (< 70 year-old) patients, in agreement with population-based studies. 10 To further characterize those patients in whom survival has improved, we analyzed the relative survival according to the clinical stage at diagnosis and found that the increased survival in the 1995-2004 cohort was concentrated in patients younger than 70 with advanced disease. In contrast, the relative survival of patients with low-risk disease (Binet A) has remained basically unchanged over the years, this being true for both the Dickman's method and the Brenner's period analysis, which is more sensitive to recent improvements in survival. However, since CLL progression rate from low-to high-risk is 2% -5% per year the 1995-2004 cohort should be followed up for a longer period of time to draw firmer conclusions.
16
When analyzing survival according to gender, there was a trend for a greater improvement of relative survival in males than in females, confirming previous observations by Brenner et al. 10 Male gender has been associated with a more advanced disease at presentation 17 and poorer biological features (e.g., unmutated IgVH genes and high expression of CD38). 18, 19 It could be argued that male patients might benefit more than females from newer therapies, but this notion has not been confirmed. 8, 20 For personal use only. on May 26, 2017. by guest www.bloodjournal.org From Although this study was not designed to respond to that question, it is tempting to link the improvement in survival to a better management, including more effective anti leukemia therapies. In fact, the two cohorts studied roughly correspond to two different periods in the history of CLL treatment: alkylators (1980) (1981) (1982) (1983) (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) and purine-analog based therapies (1995 and onwards). Of note, the group of patients whose survival has been most improved, namely those younger than 70 and with advanced stage, is that mainly treated with modern therapy. Unfortunately, however, this group of patients is not representative of the whole population of patients with CLL and, indeed, it only represents 20% of all our patients. Patients above 70 were similarly treated over the time, a large proportion of them receiving alkylating agents. In line with this, it is important to emphasize that in recent clinical trials older patients are clearly underrepresented, [3] [4] [5] 8, [21] [22] [23] which is unfortunate because, although more aggressive treatments are usually poorly tolerated by the elderly, treatment recommendations should be based on patients' general status and comorbidity rather than on age only.
24
Besides newer treatments, additional factors such as a better supportive care and the earlier detection of the disease might be contributing to the observed longer survival in more recent years. In this regard, the present study confirms that CLL is increasingly being diagnosed in patients with low-risk disease 25-27 and low tumor burden (e.g., lower blood lymphocyte counts, LDH and β 2-microglobulin serum levels). This fact is most likely due to the increasing use of routine blood tests and the availability of flow cytometry as diagnostic tool. 28 It is important to note that, in contrast with standard methods, the relative survival analysis tempers the lead-time bias that an earlier or accidental diagnosis may produce when estimating survival. 29 Our results indicate that the earlier detection of the disease does not translate by itself into a longer survival.
Indeed, relative survival for patients with low-risk clinical stage at diagnosis (Binet's A) has not significantly changed from 1980 to 2004. These findings highlight the importance of identifying better prognostic factors in patients with low disease-burden at diagnosis, as well as that of clinical trials aimed at challenging the notion that these patients should not be treated unless they progress.
30,31
In conclusion, this study shows, in a single center series, that CLL shortens life expectancy across all age groups and clinical stages, but also that survival is steadily improving, particularly in younger patients with advanced disease, most likely because of modern therapy. There is, however, an important need for improving the outcome of all patients with CLL. Lessons from recent clinical trials (e.g., key-role of chemoimmunotherapy, importance of achieving the best possible response, relevance of biomarkers such as 11q-and 17p-to select therapy, importance of microenvironmental cells in sustaining the neoplastic population, defects of T-cells) should all be taken into account when planning future treatment protocols. Only in this way the prognosis of patients with CLL will continue to improve and the ultimate goal of therapy, curing the disease, will some day become a reality. 1980 -1994 1995 -2004 P Overall (1980 -2008 Table 3 . CLL-attributable mortality for patients diagnosed in the calendar periods 1980-1994 and 1995-2004 
